Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab

Clicks: 308
ID: 118014
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #6 of 7 articles by views in journal of ophthalmology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance visual acuity (CDVA) logMAR 0.7 or better, undergoing intravitreal injections of ranibizumab, were enrolled into this prospective study. Visual function was assessed using a range of psychophysical tests, while mean foveal thickness (MFT) was determined by optical coherence tomography (OCT). Results. Group mean (±sd) MFT reduced significantly from baseline (233 (±59)) to exit (205 (±40)) ( ). CDVA exhibited no change between baseline and exit visits ( and , resp.). Measures of visual function that did exhibit statistically significant improvements ( for all) included reading acuity, reading speed, mesopic and photopic contrast sensitivity (CS), mesopic and photopic glare disability (GD), and retinotopic ocular sensitivity (ROS) at all eccentricities. Conclusion. Eyes with nv-AMD undergoing intravitreal ranibizumab injections exhibit improvements in many parameters of visual function. Outcome measures other than CDVA, such as CS, GD, and ROS, should not only be considered in the design of studies investigating nv-AMD, but also in treatment and retreatment strategies for patients with the condition.
Reference Key
sarah2013journalvisual Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sabour-Pickett, Sarah;Loughman, James;Nolan, John M.;Stack, Jim;Pesudovs, Konrad;Meagher, Katherine A.;Beatty, Stephen;Sabour-Pickett, Sarah;Loughman, James;Nolan, John M.;Stack, Jim;Pesudovs, Konrad;Meagher, Katherine A.;Beatty, Stephen;
Journal journal of ophthalmology
Year 2013
DOI
https://doi.org/10.1155/2013/268438
URL
http://dx.doi.org/10.1155/2013/268438
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:23533703 pmc3595676 doi:10.1155/2013/268438 sarah sabour-pickett james loughman stephen beatty

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.